IAM
Iambic Therapeutics, Inc.
Set alert
- YTD
- -28.98%
- 1 year
- -28.98%
- Open
- 13.10
- Prev close
- 14.28
- Mkt cap
- 636.59M
- Vol
- 476.86K
- Avg vol
- 1.06M
- EPS
- -2.69
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.40
- High
- 13.55
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.91
- 200-d avg
- 18.91
- 1y target
- 0.00
Key statistics
- Market cap
- 1.13B
- Enterprise value
- 637.77M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 61.84
- Price / book
- 0.00
- EPS (TTM)
- -2.69
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 18.25M
- Revenue growth
- 224.70%
- Free cash flow
- 0
- Total cash
- 207.88M
- Total debt
- 5.23M
- Return on equity
- 0.00%
- Shares outstanding
- 47.40M
- Short % of float
- 0.00%
- 50-day average
- 18.91
- 200-day average
- 18.91
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Iambic Therapeutics, Inc.
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- iambic.ai
News
- Iambic Therapeutics Presents Updated Clinical Results From Its IAM1363 Inhibitor At ESMO Congress 2026
- Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
- U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings
- Iambic Announces Pricing of Initial Public Offering
- Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
- Docusign Declines 7.2% Since Beating Q1 Earnings & Revenue Estimates
- New Bitdefender Survey of 1,200 Cybersecurity Professionals Reveals Top Concerns and Challenges for Businesses Globally
- Entrust Completes Acquisition of Onfido, Creating A New Era of Identity-Centric Security
- 65 Stocks Moving In Thursday's Mid-Day Session
- 45 Biggest Movers From Yesterday
Your note
Sign in to keep a note on IAM — it syncs with the Stock Master app.